Teva Pharmaceutical Industries Limited (TEVA)
TEVA trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$41.25
+0.19% on the day
Market cap
$48.1B
Large cap
Revenue · 2025
$17.3B
+4.3% on 2024
Net income · 2025
$1.4B
8.2% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | TEVA on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Israel |
| IPO year | Not reported by the screener |
| SEC CIK | 0000818686 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | L3 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $17.3B |
| Net income | $1.4B |
| Operating income | $2.2B |
| Net margin | 8.2% |
| Operating margin | 12.5% |
| Revenue growth | +4.3% |
| Cash | $3.6B |
| Total assets | $40.7B |
| P/E (computed) | 34.1× |
| P/S (computed) | 2.8× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-09-11 |
| Latest annual report | 10-K | 2026-02-03 |
| Latest quarterly / interim | 10-Q | 2026-07-29 |
| Latest current report | 8-K | 2026-09-16 |
| Latest proxy | DEFA14A | 2026-03-31 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.9% |
| 1 month | +4.7% |
| 3 months | +27.5% |
| Year to date | +31.7% |
| 1 year | +105.2% |
| From 52-week high | -0.4% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ONC | BeOne Medicines Ltd. | $349.08 | -0.38% | $39.7B |
| TAK | Takeda Pharmaceutical Company Limited | $18.52 | -0.86% | $58.5B |
| RPRX | Royalty Pharma plc Class A Ordinary Shares | $56.57 | -2.09% | $32.5B |
| ZTS | Zoetis Inc. | $74.30 | -1.78% | $30.7B |
| ALNY | Alnylam Pharmaceuticals Inc. | $223.82 | -1.41% | $29.9B |
| REGN | Regeneron Pharmaceuticals Inc. | $753.12 | -1.27% | $77.5B |
| GSK | GSK plc | $46.27 | -1.39% | $93.6B |
| SNY | Sanofi ADS | $39.12 | -1.56% | $95.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier